BRAF and melanoma: This clinical experience suggests that (i) patients with BRAFV600DK601del-mutation-positive melanoma can be treated successfully with the oral BRAF inhibitor vemurafenib and (ii) molecular screening in this context should encompass rare and complex mutations.